TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00003032
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003032
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00078845
Drug: Amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg three times a week.
Study: NCT00435461
Drug: Fluticasone furoate and fexofenadine
Normalized name: Fluticasone Furoate
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate and fexofenadine
Study: NCT04462822
Drug: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT01089010
Drug: 250 mg CK-2017357
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.
Study: NCT01089010
Drug: 500 mg CK-2017357
Normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.
Study: NCT02959918
Drug: SEL-212
Normalized name: SEL-212
DrugBank: Pegadricase (DB15129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEL-212, biologic
Study: NCT02959918
Drug: SEL-037
Normalized name: SEL-037
DrugBank: Pegadricase (DB15129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEL-037, biologic
Study: NCT02970539
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab will be administered by iv infusion and supplied as a solution at a concentration of 10 mg/mL
Study: NCT04673955
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Observation of real-life treatment with encorafenib and cetuximab
Study: NCT04673955
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Observation of real-life treatment with encorafenib and cetuximab
Study: NCT02023112
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule
Study: NCT01277913
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU once daily for 12 months
Study: NCT01277913
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 IU once daily for 12 months
Study: NCT02910219
Drug: Crofelemer
Normalized name: Crofelemer
DrugBank: Crofelemer (DB04941)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
Study: NCT02055170
Drug: finasteride 5mg oral daily
Normalized name: finasteride 5 MG
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00708903
Drug: neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HKI-272
Study: NCT00708903
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03147599
Drug: Coloverin
Normalized name: Cloverine
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine hydrochloride 135 mg
Study: NCT01124799
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg, for 9 days
Study: NCT01424241
Drug: Sandostatin LAR
Normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Open label dose escalation of Sandostatin LAR 10 mg, 20 mg, 30 mg, up to 40 mg if necessary.
Study: NCT01266005
Drug: Clevudine
Normalized name: clevudine
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg,QD
Study: NCT01266005
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg QD
Study: NCT00551525
Drug: Samarium 153
Normalized name: Samarium 153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samarium 153 lexidronam dose 2.0 mCi/kg by IV injection one time within 2 weeks (+/- 3days) after registration.
Study: NCT00442026
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
Study: NCT00442026
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
Study: NCT00442026
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
Study: NCT00287521
Drug: Latanoprost, 0.005% (Xalatan)
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One drop in the study eye(s) once daily for 28 days
Study: NCT00287521
Drug: Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One drop in the study eye(s) once daily for 28 days
Study: NCT00004999
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02697591
Drug: INCAGN01876
Normalized name: Incagn01876
DrugBank: Ragifilimab (DB18853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
Study: NCT00004999
Drug: Capravirine
Normalized name: Capravirine
DrugBank: Capravirine (DB08502)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02298088
Drug: Ticagrelor 180 mg
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor, 180 mg as early as possible after the index event and not \>24 h post event followed by 90 mg twice daily for 12 months.
Study: NCT02298088
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg clopidogrel as early as possible after the index event and not \> 24h post event, followed by 75mg/day for 12 months.~For patients with \> 75 years the recommended load dose is 75 mg instead 300 mg.
Study: NCT02258906
Drug: ulinastatin
Normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02078596
Drug: Divalproex
Normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each
Study: NCT00004999
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03001323
Drug: Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above.
Study: NCT00701103
Drug: Dalotuzumab
Normalized name: DALOTUZUMAB
DrugBank: Dalotuzumab (DB11840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT00718523
Drug: AMG 479
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
Study: NCT00877539
Drug: PF-03526299
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled, two doses 4 hours apart
Study: NCT00877539
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhaled
Study: NCT02297425
Drug: PF-06459988
Normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients
Study: NCT04319926
Drug: lidocaine topical system 1.8%
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One topical system is applied to the subject's back for 12 hours.
Study: NCT04319926
Drug: lidocaine patch 5%
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One generic lidocaine patch is applied to the subject's back for 12 hours.
Study: NCT00076310
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m\^2 IV repeated every 21 days.
Study: NCT00076310
Drug: OSI-774
Normalized name: OSI-461
DrugBank: OSI-461 (DB05415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.
Study: NCT00076310
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 IV every 21 days.
Study: NCT01541072
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation
Study: NCT01541072
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils \>= 0.5 G/L)
Study: NCT01139346
Drug: darinaparsin
Normalized name: darinaparsin
DrugBank: Darinaparsin (DB06179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
Study: NCT02080364
Drug: Azeliragon
Normalized name: Azeliragon
DrugBank: Azeliragon (DB12689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azeliragon 5mg administered orally, once daily for 18 months
Study: NCT00398047
Drug: Azacitadine and Hematopoietic Growth Factors
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Azacitadine and Hematopoietic Growth Factors
Study: NCT00939588
Drug: Aliskiren/ Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00939588
Drug: Telmisartan/ Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01758614
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all participants in this group will be given medical therapy including Aspirin 100mg per day or clopidogrel 75mg per day
Study: NCT01758614
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03964259
Drug: Intravenous fluids
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of post HDMTX intravenous fluids (IVF)
Study: NCT00833404
Drug: Nicotine transdermal patch
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
Study: NCT01568112
Drug: BG00012 (dimethyl fumarate)
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
Study: NCT01568112
Drug: ASA
Normalized name: ASA
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 325 mg microcoated aspirin (ASA)
Study: NCT00784589
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
Study: NCT00303472
Drug: Romiplostim
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00457288
Drug: TF 002
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00624832
Drug: Xolair
Normalized name: Xolair
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;
Study: NCT01737879
Drug: Peginesatide
Normalized name: Peginesatide
DrugBank: Peginesatide (DB08894)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive peginesatide for the first 24 weeks.
Study: NCT01737879
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants converted to epoetin alfa at week 25 for a total of 32 weeks
Study: NCT02797860
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparison of onset time and duration of rocuronium using Train of Four watch
Study: NCT00000332
Drug: Nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04204304
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ISO
Study: NCT00638092
Drug: sodium iodide
Normalized name: Sodium Iodide
DrugBank: Sodium iodide (DB11119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
Study: NCT00638092
Drug: Sodium Chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
Study: NCT00407342
Drug: Alefacept (drug)
DrugBank: Alefacept (DB00092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alefaceptgiven iv
Study: NCT06188325
Drug: Eliglustat
Normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form:Capsule-Route of administration:Oral
Study: NCT01310582
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01310582
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01269099
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: control group (No-PCA group)
Study: NCT03181685
Drug: Progesterone 25 MG subcutaneous
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single subcutaneous administration per day from the day of oocyte retrieval
Study: NCT03181685
Drug: Micronized progesterone 200 MG
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 vaginal administrations per day from the day of oocyte retrieval
Study: NCT03181685
Drug: Cetrorelix Acetate
Normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhibition of Luteinizing Hormone (LH) premature surge during COS
Study: NCT02217852
Drug: Nitrendipine
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.
Study: NCT02217852
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
Study: NCT00004500
Drug: Lucinactant
Normalized name: Lucinactant
DrugBank: Lucinactant (DB04897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
Study: NCT00627926
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 375 mg tablets administered orally every 8 hours at a dose of 750 mg
Study: NCT00627926
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing ≥75 kg
Study: NCT04464408
Drug: Favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily
Study: NCT00288444
Drug: Lonafarnib
Normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00288444
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00778349
Drug: Metformin solution 100 mg/mL
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03381859
Drug: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
Normalized name: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hepatitis C Virus direct-acting antiviral
Study: NCT02468999
Drug: human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01109134
Drug: tirofiban intracoronary bolus-only
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion
Study: NCT02273180
Drug: Humalog
Normalized name: HumaLOG
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Humalog 100 U/mL (dose range of 1 unit to 60 units) self-administered by deep SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycaemia.
Study: NCT02273180
Drug: Insulin glargine HOE901
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
Study: NCT01109134
Drug: tirofiban intravenous bolus plus infusion
DrugBank: Tirofiban (DB00775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administer tirofiban bolus intravenously and maintain infusion for up to 18 hours
Study: NCT00869128
Drug: Circadin
Normalized name: ZINC OXIDE 173 mg in 1 mL TOPICAL CREAM [Circadia Circa-Shield Mineral Sunscreen SPF 30]
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg prolonged-release melatonin
Study: NCT02934555
Drug: Ubiquinol
Normalized name: Ubiquinol
DrugBank: Ubiquinol (DB11340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Ubiquinol (3 mL liquid Ubiquinol).
Study: NCT00362661
Drug: Cortisol
Normalized name: Cortisol
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cortisol 10 mg/d for 3 months
Study: NCT01064362
Drug: Fondaparinux sodium
Normalized name: Fondaparinux Sodium
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
Study: NCT00005802
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005802
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005802
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005802
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03387657
Drug: Sotagliflozin (SAR439954)
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study: NCT03387657
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet~Route of administration: Oral